News
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a ...
Early commercialisation is one of the most demanding stages in bringing a therapy to market, and the challenges are only ...
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).
A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of ...
“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...
Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...
Camera fatigue: being on camera means always being on show. This can be distracting for some individuals who are constantly ...
Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...
The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...
AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...
Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results